Eom, Ki-Seong; Kim, Hee-Je; Cho, Byung-Sik; Lee, Sung Eun; Yahng, Seung-Ah; Yoon, Jae-Ho; Shin, Seung-Hwan; Jeon, Young-Woo; Kim, Jung-Ho; Kim, Yoo-Jin; Lee, Seok; Min, Chang-Ki; Cho, Seok-Goo; Kim, Dong-Wook; Lee, Jong-Wook; Min, Woo-Sung; Park, Chong-Won
Acta haematologica
2015NA ; 133 ( 3 ) :266-76.
PMID : 25413265
ÀúÀÚ »ó¼¼Á¤º¸
Eom, Ki-Seong -
Kim, Hee-Je -
Cho, Byung-Sik -
Lee, Sung Eun -
Yahng, Seung-Ah -
Yoon, Jae-Ho -
Shin, Seung-Hwan -
Jeon, Young-Woo -
Kim, Jung-Ho -
Kim, Yoo-Jin -
Lee, Seok -
Min, Chang-Ki -
Cho, Seok-Goo -
Kim, Dong-Wook -
Lee, Jong-Wook -
Min, Woo-Sung -
Park, Chong-Won -
ABSTRACT
We analyzed the outcome of stem cell transplantation (SCT) for 59 acute myeloid leukemia (AML) patients with t(8;21). The 5-year overall and disease-free survival (OS and DFS) were 70.2 and 68.4%, respectively. The 5-year cumulative incidence of relapse (CIR) and nonrelapse mortality were 16.9 and 13.6%, respectively. OS and DFS in the reduced-intensity conditioning (RIC)-SCT group (70.4%) were not different from in the autologous SCT (ASCT) group (72.4 and 69.0%, respectively). Age was a factor affecting OS (p = 0.007) and DFS (p = 0.008) in the ASCT group, but not in the RIC-SCT group. In the ASCT group, lack of the X chromosome (-X) and an age of >50 years were associated with inferior survival; however, these differences disappeared in the RIC-SCT group. CIR was significantly higher in patients with -X than in those without -X only in the ASCT group (p = 0.038), i.e. not in the RIC-SCT group. ASCT and RIC-SCT are equally effective for the intensification of postremission treatment of AML patients with t(8;21). The subgroups with advanced age or -X should be preferentially considered for RIC-SCT, rather than ASCT. Further investigations with randomized prospective trials of a sizeable study population are warranted.
Acute myeloid leukemia; t(8;21); Reduced intensity conditioning; Autologous stem cell transplantation
MESH
Adolescent, Adult, Autografts, Chromosomes, Human, Pair 21/*genetics, Chromosomes, Human, Pair 8/*genetics, Disease-Free Survival, Female, Humans, Incidence, *Leukemia, Myeloid, Acute/genetics/mortality/therapy, Male, Middle Aged, Recurrence, *Stem Cell Transplantation, Survival Rate, *Translocation, Genetic, *Transplantation Conditioning
¸µÅ©